Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BREN02
- Development stage
- Preclinical
- Lead developer
- BrainEver
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intrathecal
01
Overview
BREN02 (hEN1) is a recombinant human Engrailed-1 (EN1) protein therapy being developed by BrainEver for the treatment of Amyotrophic Lateral Sclerosis (ALS). EN1 is a homeoprotein transcription factor that is essential for the survival and maintenance of alpha-motoneurons in the spinal cord. The therapeutic approach involves the delivery of the recombinant EN1 protein, which utilizes the unique ability of homeoproteins to be internalized by cells and translocate to the nucleus. Once inside the target neurons, BREN02 regulates gene expression to provide neuroprotective and restorative effects, aiming to slow the progression of neurodegeneration and preserve motor function in patients with ALS.
- Other names
- recombinant human Engrailed-1recombinant human EN1human Engrailed-1 protein
02
Targets
EN1 (Homeobox protein engrailed-1)
Beyond the preview
Go deeper on BREN02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BREN02.